Article
FDA seeks more information on Vitrase
The FDA is looking for more analysis of data before deciding whether to approve ISTA Pharmaceuticals' ovine hyaluronidase compound for the treatment of vitreous hemorrhage.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Aerie Pharmaceuticals CEO discusses what's new in the pipeline
ImprimisRx offers a look at three new products in the pipeline
Visus CEO updates on lead product candidate, 2021 pipeline
(AAO) Genentech provides update on presentations, product portfolio
What keeps you up at night in ophthalmology: Part II
Glaucoma 360: Drug delivery contact lens technology
Glaucoma 360: Pharmaceuticals in the glaucoma industry
Related Content
